Ruchika Goel, MD, is a professor and associate vice chair of research at SIU School of Medicine.

in neonates and older children, reduced platelet increment (PI) did not lead to worse clinical outcomes, suggesting that this marker does not precipitate an increased, automatic need for transfusion.

In addition to these findings, study investigators draw attention to data that 3.6% of neonates and older children had ≥1 platelet transfusion, highlighting the importance of critically assessing transfusion practices in this population. 

“From a clinical perspective, we need to assess our adherence to the platelet transfusion guidelines and also the marker, post-transfusion platelet increment. It may be an imperfect surrogate for looking at patient-centred outcomes,” said Ruchika Goel, MD, professor and associate vice chair of research at SIU School of Medicine, in an interview with 

 “For example, if you're giving platelets as prophylaxis to prevent bleeding or as therapy to treat bleeding. From a clinician's lens, this study points to judging your effectiveness by the clinical context and the overall bleeding risk, and not just by the platelet count increment or the bump alone.”

Transfusions are the only available treatment to raise platelet counts in thrombocytopenic infants, aiming to stop or prevent bleeding. While they can prevent bleeding, platelet transfusions are associated with increased inflammation and can sometimes increase mortality or morbidity in neonates.

Goel and colleagues defined a platelet transfusion event as the issue of a platelet product by the transfusion service within the encounter start and end times. They calculated transfusion incidence as a binomial proportion of encounters during which ≥1 platelet product was issued, for the total population and by patient sex, age, and self-reported race and ethnicity.

The cohort study involved data on 249,340 inpatient encounters from 7 blood centers and 22 hospitals collected by the ​​Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric. The included patients were 0 to < 18 years of age. Investigators defined neonates as those < 28 days of age, and patients were otherwise considered older children.

Goel and colleagues observed ≥1 platelet transfusion in 3.6% of the study population (n = 8874). Of these, 3.3% were female, 3.7% were male, and the average age was 2.5 years, with a median weight of 1.6 kg.

Upon analysis of 40,779 platelet transfusion episodes, the median number per patient encounter was 2. 

In neonates, 32.2% of platelet transfusions were given at pretransfusion platelet counts < 25 × 103/µL, the remaining were given at increased pretransfusion platelet counts, including 38.5% at >25-50 × 103/µL, 19.6% at >50-100 × 103/µL, and 9.7% at >100 × 103/µL. The median transfusion dose was 14.9 mL/kg.

In older children, investigators analysed 26,570 transfusion events, with 19.0% of platelet transfusions given at pretransfusion platelet counts < 10 × 103/µL and the remaining were at higher pretransfusion platelet counts, including 3.0% at >100 × 103/µL. The median transfusion dose was 9.6 mL/kg.

Overall, investigators saw significantly elevated pretransfusion platelet count in neonates (34 × 103/µL [20-54 × 103/µL] compared with older patients (22 × 103/µL [11-40 × 103/µL]; 

 < .001). Post-transfusion PI was highest for pretransfusion platelet counts < 25 × 103/µL and decreased for higher counts, becoming negative (median, −25 × 103/µL for counts > 100 × 103/µL. Similarly, among infants and older children, PIs were highest for counts <10 × 103/µL and decreased for higher counts, becoming negative (median, −22 × 103/µL) for counts > 100 × 103/µL.

Platelet components stored in PAS had reduced odds of posttransfusion PI higher than 15 × 103/µL compared with platelet components not stored in PAS (adjusted Odds Ratio [AOR], 0.32 [95% CI, 0.27-0.37). Platelet storage > 3 days) was associated with decreased odds of PI > 15 × 103/µL (AOR, 0.67; 95% CI, 0.58-0.76 to 0.82; 95% CI, 0.76-0.88). Pathogen-reduced platelet components were associated with lower odds of achieving an increment higher than 15 × 103/µL (AOR, 0.82 [95% CI, 0.73-0.92]).

Assessing donor factors, investigators observed male sex was associated with reduced odds (AOR, 0.92; 95% CI, 0.86-0.98) of posttransfusion PI >15 × 103/µL per transfusion event. Additionally, donor age of ≥ 40 years compared with donor age 25 to < 40 years was independently associated with reduced odds of a PI >15 × 103/µL platelet increment (AOR, 0.79; 95% CI, 0.72-0.86).

In multivariable analysis, no donor or platelet characteristics were associated with a difference in risk of hospital discharge after 7 days (Adjusted Rates Ratio [ARR], 1.03; 95% Confidence Interval [CI], 0.89-1.20] for PR). Further, the rate of mortality was unchanged among platelet characteristics after an offset for the hospital length of stay of the encounter (ARR, 0.66 [95% CI, 0.42-1.04] for PR).

“A lower platelet increment should not automatically be used as a marker to lead to higher need for transfusion or, hence, an increased transfusion burden, because we are not necessarily seeing these to be related to clinical outcomes.”

References
Goel R, Karam O, Warden DE, et al. Platelet Transfusion Practices and Outcomes in Neonates and Children. 

https://doi.org/10.1001/jamanetworkopen.2025.54531

Neonatal Platelet Transfusions See Increased Inflammation, Not Reduced Bleeding. Hematology Advisor. Published November 25, 2025. Accessed February 12, 2026. 

https://www.hematologyadvisor.com/news/neonatal-platelet-transfusion-inflammation-bleeding-treatment-risk/

Podcasts

Low post-transfusion platelet increments did not predict mortality or length of stay in pediatric patients.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

When Platelet Increments Matter, With Ruchika Goel, MD

Jeffrey Downey, PhD, is a postdoctoral student at the Swirski laboratory at Icahn School of Medicine at Mount Sinai.

Interferon 1 Responsible for Causing Cardiac Events During Influenza Infection

Researchers at Mount Sinai have located a cellular mechanism responsible for the correlation between 

The connection between influenza and cardiac events has long been studied, with research from 2018 determining that patients were 6 times more likely to have a heart attack in the week after receiving a flu diagnosis. Via data obtained from the Flu and Other Respiratory Viruses Research (FOREVER) cohort, investigators saw a substantial association between respiratory infections and acute myocardial infarction.

Additionally, a study from the CDC in 2020 found that cardiac events were quite common in patients hospitalized for influenza infection. After examining >80,000 patients over 8 flu seasons, investigators found that almost 12% experienced an acute cardiovascular event. Older age, tobacco use, 

, and renal disease were significantly associated with increased risk as well.

“There’s always been an appreciation that influenza is bad for the heart; if you have a large number of cardiovascular comorbidities, influenza is going to be worse,” Jeffrey Downey, PhD, a postdoctoral student at the Swirski laboratory at Icahn School of Medicine at Mount Sinai, told 

 in an exclusive interview. “But we provided mechanistic insight as to why this may be, showing that influenza has the capacity to leave lasting scars.”

Downey and colleagues investigated the autopsies of 35 hospitalized patients who died of influenza. With these data, they discovered that >85% had ≥1 significant cardiovascular comorbidity, including 

, and cardiac fibrosis. Additionally, the team uncovered the mechanism causing cardiac damage.

Briefly after infecting the lungs, the influenza virus targeted a circulating myeloid pro-dendritic cell 3 (pro-DC3), which expressed high concentrations of chemokine receptor CCR2. The heart attracts pro-DC3 due to its production of CCL2 – after entering the heart, the virus leaves pro-DC3 and infects cardiomyocytes to trigger production of type 1 interferon (IFN-1). In turn, IFN-1 receptors engaging with cardiomyocytes cause tissue damage and compromise heart function.

Based on mouse models, the team developed a hypothetical treatment involving the dampening of IFN-1 receptors exclusively in cardiomyocytes. This protected the heart and preserved anti-viral immunity in the lung. Downey and colleagues hypothesized that a systemic delivery of modified RNA therapy to the heart’s muscle cells would modulate the IFN-1 signaling pathway.

Although this study is purely hypothesis-generating, and actual attempts at treatment are far in the future, Downey and colleagues are actively researching the use of a safe and effective systemic delivery method of this modified RNA therapeutic directly into the heart’s muscle cells rather than a direct injection used in the proof-of-concept study introducing the mod-RNA pathway. Additionally, further investigation is being conducted into pro-DC3 itself, aiming to determine the reason for its susceptibility to influenza and whether this is mirrored across other infections like SARS or COVID-19.

“Moving forward, something we should always be paying attention to is that getting through influenza may not be the only goal,” Downey said. “The main thing we should be focusing on is still prevention and mitigation of infection, but in those with high risk, we should potentially be looking at some immunotherapies that can dampen immunological pathways activated specifically in the heart.”

Editor’s Note: Downey reports no relevant disclosures.

Mount Sinai Hospital. Mount Sinai scientists uncover link between influenza and heart disease. 

. February 9, 2026. Accessed February 12, 2026. 

https://www.eurekalert.org/news-releases/1115515

Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. New England Journal of Medicine. 2018;378(4):345-353. 

Chow EJ, Rolfes MA, O’Halloran A, et al. Acute cardiovascular events associated with influenza in hospitalized adults. Annals of Internal Medicine. 2020;173(8):605-613. 

Downey J, Oliveira-Coelho A, Kiss MG, et al. Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart. Immunity. Published online February 9, 2026. 

Videos

Downey discusses the recent discovery of influenza’s interaction with the interferon 1 pathway, as well as a hypothetical method for preventing it.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Influenza

The HCPLive influenza page is a resource for medical news and expert insights on the flu. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for influenza, and more.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

Interferon 1 Responsible for Causing Cardiac Events During Influenza Infection, With Jeffrey Downey, PhD

vice president of programs, public affairs, and research at Lung Health Foundation.

New Lung Cancer Risk Calculator Streamlines Screening Eligibility, With Jessica Moffatt, PhD

The Lung Health Foundation has introduced a simplified 

 calculator designed to help patients and clinicians better understand eligibility for organized screening programs across Canada. Built on the validated PLCOm2012 risk prediction model, the online tool translates a previously spreadsheet-based calculator into a plain-language, 10-question interface that generates a 6-year lung cancer risk estimate in 2 – 3 minutes.

Lung cancer screening differs from other cancer screening programs in that it is risk-based rather than population-based. Patients must meet age criteria and have a sufficient smoking history before undergoing a formal risk assessment through a provincial program. That multi-step structure can create uncertainty in primary care settings, particularly during time-limited visits.

, investigator Jessica Moffatt, PhD, vice president of programs, public affairs, and research at Lung Health Foundation, emphasized that the calculator does not diagnose cancer and does not determine formal screening eligibility.

“The only official risk assessment result is the risk assessment result that's conducted with the screening program,” Moffatt said. “What this can do is this can be supplemental to that clinician-patient conversation to really help facilitate that informed decision-making process between the clinician and the patient to help the clinician understand, should I make the referral for screening? Once that referral is made, the official risk assessment is conducted. This is just a tool to help the clinician understand, is my patient actually eligible, or may they be eligible for lung cancer screening?”

The calculator produces a downloadable PDF summary without jargon, allowing patients to bring their responses into an appointment. Developers said this feature was designed with primary care workflows in mind, enabling clinicians to review key inputs, such as age, smoking exposure, comorbidities, and prior cancer history, without navigating a complex risk model during the visit.

The tool may also benefit individuals without a regular primary care provider. In some provinces, patients can self-refer to lung cancer screening programs. A preliminary risk estimate may help them decide whether contacting a screening site is warranted.

The PLCOm2012 model is structured to balance benefit and harm. Low-dose CT screening carries risks, including false positives and downstream procedures. By anchoring the calculator in an established risk framework, the Lung Health Foundation aims to support appropriate screening conversations while reinforcing that patients with symptoms, such as persistent cough, hemoptysis, or unexplained weight loss, require diagnostic evaluation rather than screening.

With many lung cancers still diagnosed at advanced stages, the Lung Health Foundation positions the calculator as an entry point to informed discussions, not a substitute for clinical judgment.

“We recognize how busy primary care providers are, and this is a tool that can help primary care providers, in a very streamlined way, have that discussion with their patient that lung cancer screening may be right for them,” Moffatt said. “It's convenient for the public, but it's also convenient for clinicians.”

‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point. GlobeNewswire. Published on February 4, 2026. Accessed on February 12, 2026. 

https://finance.yahoo.com/news/think-mortgage-calculator-lung-cancer-123000493.html?guccounter=1&guce_referrer=aHR0cHM6Ly9zdGF0aWNzLnRlYW1zLmNkbi5vZmZpY2UubmV0Lw&guce_referrer_sig=AQAAANFnUl3Oz4FMn8kNg43vqehf_7SF1nUmh0k1LLaCpbMdC9_T-6vswljrh6fwLmRxxEGMwz-0dnFQjGKKfqJJWi0oQETyZDsfkBeYGnzfUqTpyxdDpQumjFy3NQ7FXywWocCd8t8GXlRUV3iH2g3ONrsSgg6yIeNYhnHt2F9RSZuO

The free, user-friendly calculator provides a 6-year lung cancer risk estimate to help patients and clinicians assess screening eligibility.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lung Cancer

Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

New research is shedding light on healthcare provider (HCP) perceptions and prescribing patterns of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI).

The real-world survey findings suggest HCPs consider multiple factors when determining an appropriate PERT choice and indicate prescribing a variety of PERT products, influenced most heavily by abdominal and bowel symptom control, affordability, and formulary or insurance coverage.

A condition in which the small intestine cannot digest food completely because of problems with digestive enzymes from the pancreas, EPI management relies heavily on PERT to substitute for the missing digestive enzymes. PERT products like Creon, Zenpep, Pancreaze, Viokace, and Pertzye are all composed of pancrelipase but differ in formulation-specific attributes and access/coverage considerations.

“HCPs must consider multiple factors when selecting a PERT product for a given patient,” Jodie Barkin, MD, an associate professor of Clinical Medicine at the University of Miami Miller School of Medicine, and colleagues wrote.1 “Understanding their decision-making process and preferences for different PERT products can offer valuable insights into real-world clinical practice and support optimal care for patients with EPI. However, the current literature lacks comprehensive real-world studies describing how HCPs in the United States manage PERT therapy and perceive different PERT products.”

To assess real-world EPI management practice and HCP perceptions of PERT products in the United States, investigators carried out an online survey with HCPs who had treated patients with EPI for ≥ 3 years and prescribed PERT products to ≥ 10 patients over a 12-month period.

The survey collected de-identified data on HCP characteristics, prescribing patterns, and perceptions of PERT products across the domains of efficacy, convenience, and access. Of note, survey responses were self-reported by HCPs. No patient-level data were collected; all responses were based on HCP recollection, including aggregated patient characteristics using questions that asked respondents to report the characteristics of their patients.

A total of 250 HCPs were surveyed, including 124 specialists, 95 generalists, and 31 advanced practice providers. HCPs managed a median of 30 patients with EPI on PERT in the 12 months preceding the survey.

Results showed the most commonly prescribed PERT products were Creon (84.0%), Zenpep (60.4%), and Pancreaze (59.2%), with fewer HCPs prescribing Viokace (27.2%) and Pertzye (16.0%). Specific factors considered in prescribing decisions included improvement in abdominal and bowel symptoms (83.6%), affordability (72.4%), and formulary/insurance coverage (72.0%).

Investigators noted a significantly greater proportion of HCPs reported favorable perceptions of Creon over other PERT products.

Perceptions of formulary/insurance coverage across PERT products varied, with 8.0–56.0% of HCPs agreeing or strongly agreeing that a prescribed product had good coverage.

Investigators pointed out these findings were generally consistent across different provider types.

“This US-based survey study offered valuable insights into HCPs considerations when managing patients with EPI using PERT products, as well as their perceptions of individual products,” investigators concluded.1 “These findings may help to inform decision-making by clinicians and healthcare payers that could ultimately support improved quality and continuity of care for EPI patients. Various factors may contribute to barriers in treatment access and should be addressed to ensure equitable and timely access to PERT.”

Ashkar M, Geremia J, Baldwin Z, et al. Prescribing Patterns and Perceptions of Pancreatic Enzyme Replacement Therapy among Healthcare Providers: A Prospective United States Healthcare Providers Survey. 

. Published online January 12, 2026. doi:10.1007/s12325-025-03454-7

NIDDK. Exocrine Pancreatic Insufficiency (EPI). Accessed February 12, 2026. 

https://www.niddk.nih.gov/health-information/digestive-diseases/exocrine-pancreatic-insufficiency/definition-facts

Cleveland Clinic. Exocrine Pancreatic Insufficiency (EPI). Accessed February 12, 2026. 

https://my.clevelandclinic.org/health/diseases/21577-exocrine-pancreatic-insufficiency-epi

Articles

US healthcare providers managing exocrine pancreatic insufficiency report that pancreatic enzyme replacement therapy selection is driven primarily by abdominal and bowel symptom control, affordability, and payer/formulary constraints. In a self-reported online survey of 250 clinicians with established EPI experience, Creon, Zenpep, and Pancreaze were most commonly prescribed, while Viokace and Pertzye were used less frequently. Favorability ratings were highest for Creon versus other products. Perceived insurance coverage varied widely across agents, suggesting access remains a major determinant of continuity and equity in therapy.

Survey findings highlight abdominal and bowel symptom control, affordability, and formulary or insurance coverage as factors driving perceptions and prescribing patterns of PERT.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Real-World Prescribing Patterns of PERT in Exocrine Pancreatic Insufficiency

Mark Kaufmann, MD, is a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City.

Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD

The world of billing effectiveness among clinicians in 

 can be daunting for some, as healthcare coding, billing, and related impacts on the financial stability of practices are ever-changing in the field of medicine.

A session on this topic was presented at the 

 by Mark Kaufmann, MD, a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City. Kaufmann spoke on-site at the conference with 

 regarding this talk and its biggest highlights for clinicians in dermatology who want to improve their billing effectiveness.

“I think one of the more important things that I discussed was really where we are and how we got here, and I think it's really important…because we're living in an environment of decreasing reimbursements and increasing costs,” Kaufmann expressed. “In order to keep our doors open, we need to think about efficiencies.”

Kaufmann pointed to the importance of implementing the entire fee schedule, rather than only the 20 or more codes used on a daily basis. He also stressed the value of considering alternative revenue streams for the medical office. Over the previous 25 years, Kaufmann noted, the reimbursement has been effectively decreasing.

“The Congress came out last year and said they were giving us a two-and-a-half percent upwards correction, and that's true, but even when you take that into account, we're still not just lower than we were 25 years ago,” Kaufmann said. “We're lower than we were three years ago, and so effectively, we're being cut every year, even when the buzz is that we're getting increases.”

Later, Kaufmann highlighted efficiencies being improved through artificial intelligence (AI) scribes. Thanks to AI scribes, Kaufmann described notes as improved, along with coding and compliance.

The quotes used in Kaufmann’s interview video were edited for the purposes of clarity.

Kaufmann has previously disclosed serving as a consultant for companies such as Apogee Therapeutics, Avita Medical, and Biofrontera, and he has held a position on the medical advisory board for Modernizing Medicine, Inc.

Kaufmann M, Siegel D. How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Burks K, Shields J, Flesher S, et al. A systematic review of outpatient billing practices. SAGE Open Med. 2022 May 23;10:20503121221099021. 

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Diagnostic Performance of NITs Across MASLD Subgroups, With Zobair Younossi, MD, MPH

Frank Gonzalez is an attending physician at Children’s Hospital Los Angeles and an assistant professor of clinical pediatrics at Keck School of Medicine of USC.

Gonzalez explains how new findings in weather-related emergency department visits and pain in pediatric sickle cell disease can guide clinicians. 


Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Managing Climate Change-Induced Sickle Cell Pain Crises With Frank Gonzalez, MD

David Rizik, MD, is an interventional cardiologist at Banner University Health.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

Banner Health Debuts AI 3D Vascular Modeling Device, With David Rizik, MD, and Michael Morris, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Seasonal IgE Surge in Birch Allergy Driven by IgE⁺ Plasmablasts: Q&A With Investigators

The data represent the highest and most significant improvement in AHV and the first statistically significant improvement in body proportionality in achondroplasia.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial

Ashfaq Marghoob, MD, is a dermatologist specializing in the diagnosis and treatment of cancers of the skin and the director of the Memorial Sloan-Kettering regional skin cancer clinic.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

Discussing Pediatric Dermoscopy and AI for Skin Cancer Detection, With Ashfaq Marghoob, MD

Desai discusses his recent observational cohort study indicating finerenone’s substantial reduction of heart failure exacerbation risk in patients with HFpEF.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Finerenone Outperforms Spironolactone for Heart Failure Exacerbation in HFpEF, With Nihar Desai, MD, MPH

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The American Society of Hematology released new 2026 Guidelines for Management of Relapsed/Refractory ALL in AYAs, discussing immunotherapy and personalized decision making. 


ASH Releases 8 Recommendations for Relapsed, Refractory Acute Lymphoblastic Leukemia in Adolescents, Young Adults

This interview with Marghoob was held on-site at Maui Derm, highlighting tips on dermoscopy and skin cancer detection from Marghoob’s workshop presentation.

Tips on Dermoscopy and Skin Cancer Detection, With Ashfaq Marghoob, MD

Jonggi Choi, MD, PhD, is an associate professor at Asan Medical Center, University of Ulsan College of Medicine, and visiting scholar at Mass General Hospital.

Choi explains longstanding hesitancy around statin use in chronic liver disease, particularly cholestatic diseases like PBC, and how his research challenges these sentiments.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Latest News

When Platelet Increments Matter, With Ruchika Goel, MD

Interferon 1 Responsible for Causing Cardiac Events During Influenza Infection, With Jeffrey Downey, PhD

Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD

Real-World Prescribing Patterns of PERT in Exocrine Pancreatic Insufficiency

Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD